Postgrad LIVE! Study Fairs

Southampton | Bristol

University of Leeds Featured PhD Programmes
University of West London Featured PhD Programmes
University of Kent Featured PhD Programmes
University of Portsmouth Featured PhD Programmes
University of Nottingham Featured PhD Programmes
United Kingdom
Bradford×
10 miles

Cancer / Oncology PhD Projects, Programs & Scholarships in Bradford

We have 31 Cancer / Oncology PhD Projects, Programs & Scholarships in Bradford

  • Cancer / Oncology×
  • United Kingdom×
  • Bradford×
  • clear all
Order by 
Showing 1 to 10 of 31
  Posttranslational modifications of the tumor suppressor PTCH1: characterisation and functional significance
  Dr N.A. Riobo-Del Galdo, Prof R.W. Bayliss
Application Deadline: 10 March 2019
PTCH1, the receptor of the Hedgehog family of proteins and a well-characterised tumor suppressor, is a 12-transmembrane protein with long intracellular N- and C-termini (1).
  Epigenetics and Cancer: Determining how Mistakes in V(D)J Recombination Trigger Leukaemias and Lymphomas
  Research Group: School of Molecular and Cellular Biology
  Dr J Boyes
Applications accepted all year round
V(D)J recombination is essential to produce an effective adaptive immune system but since the reaction involves the breakage and rejoining of DNA, it is highly dangerous and errors have long been thought to lead to leukaemias and lymphomas.
  Epigenetics and Cancer: Development of Novel Tools to Determine how Aberrant V(D)J Recombination Reactions Cause Leukaemia
  Dr J Boyes
Applications accepted all year round
V(D)J recombination generates a highly diverse set of immunoglobulin and T cell receptor genes to enable vertebrates to fight a vast range of infections.
  Targeting addiction to a breast cancer metastasis survival pathway by inhibition of RAN GTPase
  Research Group: Institute of Cancer Therapeutics
  Dr S Shnyder, Prof M El-Tanani, Dr S Betmouni
Applications accepted all year round
Metastatic cancer is a major global health burden. Each year, eleven million new cases of cancer are diagnosed worldwide, including 5 million cases in industrialized countries.
  Ran GTPase as a potential novel therapeutic target in EMT transdifferentiation and breast cancer stem cell (BCSC) survival during metastatic development
  Research Group: Institute of Cancer Therapeutics
  Prof R Morgan, Prof M El-Tanani, Dr M Isreb, Dr M Najafzadeh
Applications accepted all year round
Breast cancer is the leading cause of cancer death in women worldwide. Accumulating evidence suggests that local disease recurrence and metastatic lesions, the major causes of patient mortality, are due to a subset of aggressive cells termed cancer stem cells (CSCs).
  Aldehyde dehydrogenase expression and function in cancer stem cells
  Research Group: Institute of Cancer Therapeutics
  Dr K Pors, Dr A Mardaryev, Prof A Locke
Applications accepted all year round
Aldehyde dehydrogenases (ALDHs) catalyse the oxidation and detoxification of reactive endogenous and exogenous aldehydes into carboxylic acids via NAD+ coupled reduction.
  Leeds/AstraZeneca CASE: Structural mechanisms of fibroblast growth factor receptor signalling at the membrane interface
  Research Group: Astbury Centre for Structural Molecular Biology
  Prof A.L. Breeze, Prof F. Sobott
Application Deadline: 28 February 2019
Fibroblast growth factor receptors (FGFRs) are receptor tyrosine kinases that play key roles in embryo development, tissue remodelling, wound healing, and cancer.
  Identification and functional characterisation of BRIT1/MCPH1 synthetic lethal genes to treat breast and ovarian cancer
  Dr S Bell, Prof C A Johnson
Applications accepted all year round
Women who have undergone surgery for breast and ovarian cancer often have additional chemotherapy to kill residual cancer cells and prevent recurrence.
  Understanding drug-resistance in myeloid cancer
  Dr P Laslo
Applications accepted all year round
Under pathogenic challenges, cells of the innate system become epigenetically reprogrammed and establish immune memory.
  Prodrugs Activated by Tumour Microenvironment
  Research Group: Institute of Cancer Therapeutics
  Dr R Wheelhouse, Prof P Loadman, Prof R M Phillips
Applications accepted all year round
The anticancer drug temozolomide (TMZ), has been in the clinic for treating brain tumours for nearly 30 years. Despite its “Blockbuster” status, no other compounds of this class have reached clinical trial.
Show 10 15 30 per page


FindAPhD. Copyright 2005-2019
All rights reserved.